报价延迟最少15分钟:2025/07/18 16:31 EDT
盘后时段
|
||||
|
3.19 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.1155
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.01/-1.57
|
|
企业价值
19.22M
|
| 资产负债 |
|
每股账面净值
3.59
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
11.20M
|
|
每股收益
0.01
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/18 16:31 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology. |
